1. Home
  2. FDMT vs VOR Comparison

FDMT vs VOR Comparison

Compare FDMT & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo 4D Molecular Therapeutics Inc.

FDMT

4D Molecular Therapeutics Inc.

HOLD

Current Price

$9.50

Market Cap

515.6M

Sector

Health Care

ML Signal

HOLD

Logo Vor Biopharma Inc.

VOR

Vor Biopharma Inc.

HOLD

Current Price

$15.52

Market Cap

755.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FDMT
VOR
Founded
2013
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
515.6M
755.7M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
FDMT
VOR
Price
$9.50
$15.52
Analyst Decision
Strong Buy
Buy
Analyst Count
7
10
Target Price
$31.71
$45.33
AVG Volume (30 Days)
783.4K
1.2M
Earning Date
05-07-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
18.79
N/A
EPS
N/A
N/A
Revenue
$85,209,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$70.28
N/A
P/E Ratio
N/A
N/A
Revenue Growth
230194.60
N/A
52 Week Low
$2.89
$0.13
52 Week High
$12.34
$49.95

Technical Indicators

Market Signals
Indicator
FDMT
VOR
Relative Strength Index (RSI) 50.86 52.12
Support Level $8.41 $11.38
Resistance Level $9.78 $16.88
Average True Range (ATR) 0.64 1.62
MACD -0.01 -0.01
Stochastic Oscillator 44.44 40.99

Price Performance

Historical Comparison
FDMT
VOR

About FDMT 4D Molecular Therapeutics Inc.

4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).

About VOR Vor Biopharma Inc.

Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.

Share on Social Networks: